N. Jim Rhodes, Pharm.D., M.S., BCPS

Associate Professor
Downers Grove, IL

Home / Academics / Our Faculty / N. Jim Rhodes, Pharm.D., M.S., BCPS


Dr. N. Jim Rhodes, PharmD, MSc, BCPS AQ-Infectious Diseases completed his Doctor of Pharmacy degree at the University of Florida and a Master of Science in Clinical Investigations at Northwestern University. He also completed four years of post-graduate training including a pharmacy practice residency, a specialty infectious diseases residency, and a two-year fellowship in Infectious Diseases Pharmacotherapy focusing on clinical outcomes and pharmacometrics. Dr. Rhodes is currently an Associate Professor at Midwestern University where he serves as a clinical and didactic instructor in infectious diseases therapeutics and clinical pharmacokinetics. In 2018, he joined the Midwestern University Pharmacometrics Center of Excellence. In 2020, he released a user interface for the Optimal Data Analysis non-parametric machine learning algorithm which is available in R. He is engaged in clinical-translational research at Midwestern University and Northwestern Memorial Hospital, where he practices clinically in acute-care infectious diseases and antimicrobial stewardship. He actively participates in infectious diseases organizations, publication peer-reviews, extramural funding reviews, and continuing education content for clinical pharmacy specialties.

Associate Professor

Downers Grove, IL

College of Pharmacy
Downers Grove Campus

Pharmacy Practice


Call My


Send Me
a Message



| 2018 | AQ-ID
Northwestern University | 2015 | M.SC
University of Florida | 2011 | Pharm.D.

Courses Taught

Representative courses lecturing in:

PPRAD 1663: Pharmacotherapeutics IV  (Spring)

PHARD 1671: Evidence Based Pharmacy Practice (Fall)

PPRAD 1301: Introduction to Research Elective (rolling)


Dr. Rhodes’s interests include anti-infective pharmacokinetics and pharmacodynamics, clinical outcomes, and predictive modeling. His research is primarily focused on clarifying the antimicrobial-exposure-response profiles in clinical and translational models. His research program also seeks to evaluate how contemporary antimicrobial utilization influences resistance and clinical outcomes. He is actively involved in mentoring post-doctoral PharmD residents and fellows. For more information about the Infectious Diseases Pharmacotherapy Fellowship, see the following link.


Selected publications from over 60 peer reviewed manuscripts:

  1. Censi M, Rhodes NJ, Gettig JP, Lullo A, Borchert J. Effects of Advanced Pharmacy Practice Experience Characteristics on Postgraduate Year 1 Residency Match Rates. J Pharm Pract. 2020 Sep 15:897190020958263. doi:10.1177/0897190020958263. Epub ahead of print. PMID: 32930028.

  2. Pincus NB, Bachta KER, Ozer EA, Allen JP, Pura ON, Qi C, Rhodes NJ, Marty FM, Pandit A, Mekalanos JJ, Oliver A, Hauser AR. Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed Pseudomonas aeruginosa Clonal Complex 446 in an Academic Medical Center. Clin Infect Dis. 2020 Sep 12;71(6):1524-1531. doi: 10.1093/cid/ciz973. PMID: 31583403; PMCID:

  3. Liu J, Rhodes NJ, Roberts JA, Pais GM, Turner B, Kiel PJ, Scheetz MH. β-lactam dosing strategies: Think before you push. Int J Antimicrob Agents. 2020 Aug 31:106151. doi: 10.1016/j.ijantimicag.2020.106151. Epub ahead of print. PMID: 32882430.

  4. Al-Shaer MH, Neely MN, Liu J, Cherabuddi K, Venugopalan V, Rhodes NJ, Klinker K, Scheetz MH, Peloquin CA. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. Antimicrob
    Agents Chemother. 2020 Aug 20;64(9):e00745-20. doi: 10.1128/AAC.00745-20. PMID: 32601155; PMCID: PMC7449216.

  5. Liu J, Neely M, Lipman J, Sime F, Roberts JA, Kiel PJ, Avedissian SN, Rhodes NJ, Scheetz MH. Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. Clin Pharmacokinet. 2020 Aug;59(8):1027-1036. doi:
    10.1007/s40262-020-00873-3. PMID: 32140940; PMCID: PMC7222999.

  6. Avedissian SN, Pais GM, Liu J, Rhodes NJ, Scheetz MH. Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction? Clin Infect Dis. 2020 Jul 11;71(2):426-432. doi: 10.1093/cid/ciz1189. PMID: 31833540.

  7. Hoff BM, Scheetz MH, Jain M, Cullina JF, Rhodes NJ. Exploring the Relationship between FEV1 Loss and Recovery and Aminoglycoside Pharmacokinetics in Adult Patients with Cystic Fibrosis: Implications for Clinical Dosing Strategies. Pharmacotherapy. 2020 Jun;40(6):584-591. doi: 10.1002/phar.2399. Epub 2020 May 5. PMID: 32259317.

  8. Pais GM, Liu J, Zepcan S, Avedissian SN, Rhodes NJ, Downes KJ, Moorthy GS, Scheetz MH. Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention. Pharmacotherapy. 2020 May;40(5):438-454. doi: 10.1002/phar.2388. Epub 2020 May 4. PMID: 32239518; PMCID: PMC7331087.

  9. Pais GM, Liu J, Avedissian SN, Hiner D, Xanthos T, Chalkias A, d'Aloja E, Locci E, Gilchrist A, Prozialeck WC, Rhodes NJ, Lodise TP, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH. Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. J Antimicrob Chemother. 2020 May 1;75(5):1228-1236. doi: 10.1093/jac/dkz563. PMID: 32011685.

  10. Liu J, Pais GM, Avedissian SN, Gilchrist A, Lee A, Rhodes NJ, Hauser AR, Scheetz MH. Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational In Vivo Rat Model. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02300-19. doi: 10.1128/AAC.02300-19. PMID: 32071049; PMCID: PMC7179599.

  11. Wagner JL, Rhodes NJ, Scheetz MH, Bosso JA, Goff DA, Rybak MJ, Davis SL; MAD-ID Research Network. Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. Int J Antimicrob Agents. 2020 Jun;55(6):105970. doi: 10.1016/j.ijantimicag.2020.105970. Epub 2020 Apr 10. PMID: 32283176.

  12. Mahmoud A, Shah A, Nutley K, Nicolau DP, Sutherland C, Jain M, Scheetz MH, Rhodes NJ. Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. J Glob Antimicrob Resist. 2020 Jun;21:83-85. doi: 10.1016/j.jgar.2020.03.003. Epub 2020 Mar 19. PMID: 32200125.

  13. Wong G, Taccone F, Villois P, Scheetz MH, Rhodes NJ, Briscoe S, McWhinney B, Núñez-Núñez M, Ungerer J, Lipman J, Roberts J. Beta-lactam pharmacodynamics in Gram Negative bloodstream infections in the critically ill. J Antimicrob Chemother. 2019 Oct 26. pii: dkz437. doi: 10.1093/jac/dkz437. PMID: 31665353.
  14. Avedissian SN, Rhodes NJ, Kim Y, Bradley J, Valdez JL, Le J. Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. J Antimicrob Chemother. 2019 Oct 24. pii: dkz408. doi: 10.1093/jac/dkz408. PMID: 31648297
  15. Fjortoft N, Gettig J, Rhodes NJ, Scheetz MH. Writing and Thinking. Am J Pharm Educ. 2019. Accepted August 2019. ajpe7785
  16. Rhodes NJ, Wagner JL, Davis SL, Bosso JA, Goff DA, Rybak MJ, Scheetz MH; MAD-ID Research Network. Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00327-19. doi: 10.1128/AAC.00327-19. Print 2019 Jul. PMID: 31061154.
  17. Avedissian SN, Rhodes NJ, Ng TMH, Rao AP, Beringer PM. The Potential for QTc Prolongation with Chronic Azithromycin Therapy in Adult Cystic Fibrosis Patients. Pharmacotherapy. 2019 May 2. doi: 10.1002/phar.2270. [Epub ahead of print]. PMID: 31045258.
  18. Kabakov A, Rhodes NJ, Wenzel R. Discrepancies Between Patient Self-Reported and Electronic Health Record Documentation of Medication Allergies and Adverse Reactions in the Acute Care Setting: Room for Improvement. J Pharm Technol. 2019. 35(4):139-145. doi: 10.1177/8755122519840700. Epub 2019 April 9.
  19. Pais GM, Avedissian SN, O'Donnell JN, Rhodes NJ, Lodise TP, Prozialeck WC, Lamar PC, Cluff C, Gulati A, Fitzgerald JC, Downes KJ, Zuppa AF, Scheetz MH. Comparative performance of urinary biomarkers for vancomycin induced kidney injury according to timeline of injury. Antimicrob Agents Chemother. 2019 Apr 15. pii: AAC.00079-19. doi: 10.1128/AAC.00079-19. PMID: 30988153.
  20. Hammond DA, McCreary EK, Rech MA, Smith MN, Yeo QM, Lusardi K, Rhodes NJ, Swanson J, Bland CM. Perceptions and Practices for Beta-Lactam Antibiotic Dosing, Administration, and Monitoring in Critically Ill Patients: Current Views and Use among Critical Care and Infectious Diseases Pharmacists. J Am Coll Clin Pharm. 2019. Epub ahead of print. doi:10.1002/jac5.1084
  21. Avedissian SN, Liu J, Rhodes NJ, Lee A, Pais GM, Hauser AR, Scheetz MH. A Review of the Clinical Pharmacokinetics of Polymyxin B. Antibiotics (Basel). 2019 Mar 22;8(1). pii: E31. doi: 10.3390/antibiotics8010031. Review. PMID: 30909507.
  22. Christensen AB, Barr VO, Martin DW, Anderson MM, Gibson AK, Hoff BM, Sutton SH, Widmaier V, Salim AA, Silkaitis C, Qi C, Zembower TR, Postelnick MJ, Rhodes NJ. Diagnostic stewardship of C. difficile testing: a quasi-experimental antimicrobial stewardship study. Infect Control Hosp Epidemiol. 2019 Mar;40(3):269-275. doi: 10.1017/ice.2018.336. PMID: 30786942.
  23. Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin Area under the Curve and Acute Kidney Injury: A Meta-analysis. Clin Infect Dis. 2019 Feb 1. doi: 10.1093/cid/ciz051. [Epub ahead of print] PMID: 30715208.
  24. Avedissian SN, Pais G, Joshi MD, Rhodes NJ, Scheetz MH. A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime. mSphere. 2019 Jan 30;4(1). pii: e00595-18. doi: 10.1128/mSphere.00595-18. PMID: 30700511.
  25. Avedissian SN, Rhodes NJ, Liu J, Aljefri D, Postelnick MJ, Sutton SH, Zembower TR, Martin D, Pais G, Cruce CE, Scheetz MH. Understanding the components, calculation and impact of monthly and seasonal variation of the SAAR: Illustrative Data. Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.01780-18. doi: 10.1128/AAC.01780-18. [Epub ahead of print]. PMID: 30602510.

    Complete List of Published Work in My Bibliography:



Organizations, Committees, and Service
American Society of Health system Pharmacists (ASHP)        (July 2011 – Present)
                Midyear Educational Steering Committee                (Sept 2016 – Dec 2018)
                          Core Therapeutics Module Faculty                 (Nov 2014 – Dec 2018)
Infectious Diseases Pharmacy Specialty Review Faculty         (Oct 2017 – Dec 2018)

American College of Clinical Pharmacy (ACCP)                       (July 2012 – Present)

American Society for Microbiology (ASM)                                 (August 2013 – Present)

Society for Healthcare Epidemiology of America (SHEA)         (August 2018 – Present) 

Society of Infectious Diseases Pharmacists (SIDP)                  (Sept 2012 – Present)    
                                           Research Committee                      (Sept 2014 – October 2018)
                                      Recognitions Committee                      (October 2018 – Present)


Rhodes NJ (PI). Midwestern University/Downers Grove, Development of a Clinical Decision Algorithm for Adults Hospitalized With Pneumonia. 2020 New Investigator Award. American Association of Colleges of Pharmacy.


SIDP Young Investigator Award 2019: Awarded October 1, 2019 in recognition of research accomplishments of young investigators who show research promise in infectious diseases.

MWU CCP New Preceptor Excellence Award 2018-2019: Awarded May 22, 2019 in recognition of excellence in precepting Midwestern University CCP students on rotation.

Publons Sentinels of Science Award. September 2016. For excellence in peer review of scientific literature in the areas of pharmacology, toxicology, and pharmaceutics.